524 related articles for article (PubMed ID: 15639692)
21. Carbapenems: a potent class of antibiotics.
Nicolau DP
Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
[TBL] [Abstract][Full Text] [Related]
22. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
Kim A; Kuti JL; Nicolau DP
Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
[TBL] [Abstract][Full Text] [Related]
23. In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.
Hikida M; Itahashi K; Igarashi A; Shiba T; Kitamura M
Antimicrob Agents Chemother; 1999 Aug; 43(8):2010-6. PubMed ID: 10428928
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms.
Yang K; Guglielmo BJ
Ann Pharmacother; 2007 Sep; 41(9):1427-35. PubMed ID: 17666573
[TBL] [Abstract][Full Text] [Related]
26. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN
West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
[TBL] [Abstract][Full Text] [Related]
27. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
Harada S; Ishii Y; Yamaguchi K
Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
[TBL] [Abstract][Full Text] [Related]
28. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.
Kohler J; Dorso KL; Young K; Hammond GG; Rosen H; Kropp H; Silver LL
Antimicrob Agents Chemother; 1999 May; 43(5):1170-6. PubMed ID: 10223931
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.
Dalhoff A; Schubert S; Vente A
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193648
[TBL] [Abstract][Full Text] [Related]
30. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
Bauernfeind A; Jungwirth R; Schweighart S
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418
[TBL] [Abstract][Full Text] [Related]
31. Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Robert J; Pantel A; Merens A; Meiller E; Lavigne JP; Nicolas-Chanoine MH;
BMC Infect Dis; 2017 Jan; 17(1):78. PubMed ID: 28095794
[TBL] [Abstract][Full Text] [Related]
32. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
[TBL] [Abstract][Full Text] [Related]
33. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.
Eagye KJ; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2007 Apr; 8(2):215-26. PubMed ID: 17437367
[TBL] [Abstract][Full Text] [Related]
34. [In vitro susceptibility testing of 446 clinical isolates of gram-positive bacteria to new quinolones, carbapenems and cephalosporins].
Cereda RF; Pignatari AC; Leme IL; Jones RN; Sader HS
Rev Assoc Med Bras (1992); 1996; 42(3):130-4. PubMed ID: 9138353
[TBL] [Abstract][Full Text] [Related]
35. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases.
Sanders CC; Sanders WE; Thomson KS; Iaconis JP
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():187-96. PubMed ID: 2808207
[TBL] [Abstract][Full Text] [Related]
36. An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
García-Fernández A; Miriagou V; Papagiannitsis CC; Giordano A; Venditti M; Mancini C; Carattoli A
Antimicrob Agents Chemother; 2010 Oct; 54(10):4178-84. PubMed ID: 20660683
[TBL] [Abstract][Full Text] [Related]
37. Extended-spectrum plasmid-mediated beta-lactamases.
Sirot D
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():19-34. PubMed ID: 8543494
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of bacterial isolates from Turkey--a report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program.
Eraksoy H; Basustaoglu A; Korten V; Kurt H; Ozturk R; Ulusoy S; Yaman A; Yuce A; Zarakolu P;
J Chemother; 2007 Dec; 19(6):650-7. PubMed ID: 18230545
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteria].
Gales AC; Pignatari AC; Jones RN; Baretta M; Sader HS
Rev Assoc Med Bras (1992); 1997; 43(2):137-44. PubMed ID: 9336049
[TBL] [Abstract][Full Text] [Related]
40. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
Hellinger WC; Brewer NS
Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
